BI 764532
Boehringer Ingelheim
['ca,022,i', 'ca,022,1']
5: as of dec 2022, 90 patients have received 1 dose of bi 764532. notably, the mtd has not been reached and dose escalation continues. most common treatment-related aes included crs, pyrexia, decreased lymphocytes, asthenia, and dysgeusia. #cancerresearch #asco23 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer